JP2011517683A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011517683A5 JP2011517683A5 JP2011503961A JP2011503961A JP2011517683A5 JP 2011517683 A5 JP2011517683 A5 JP 2011517683A5 JP 2011503961 A JP2011503961 A JP 2011503961A JP 2011503961 A JP2011503961 A JP 2011503961A JP 2011517683 A5 JP2011517683 A5 JP 2011517683A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- unsubstituted
- alkyl
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 145
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 32
- 230000002209 hydrophobic effect Effects 0.000 claims description 28
- 239000002105 nanoparticle Substances 0.000 claims description 25
- 125000003118 aryl group Chemical group 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 13
- 238000004090 dissolution Methods 0.000 claims description 10
- 102000014914 Carrier Proteins Human genes 0.000 claims description 8
- 108010078791 Carrier Proteins Proteins 0.000 claims description 8
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000012453 solvate Substances 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 7
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 102000009027 Albumins Human genes 0.000 claims description 4
- 108010088751 Albumins Proteins 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 241000288906 Primates Species 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 229940123237 Taxane Drugs 0.000 claims description 2
- 229920000249 biocompatible polymer Polymers 0.000 claims description 2
- 230000015556 catabolic process Effects 0.000 claims description 2
- 238000006731 degradation reaction Methods 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 125000001165 hydrophobic group Chemical group 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 210000003462 vein Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 10
- RCINICONZNJXQF-VAZQATRQSA-N CC(C)([C@@](C1)([C@H](C([C@]2([C@@H](C[C@@H]3O)OC2)OC(C)=O)[C@]3(C)C([C@@H]2OC(C)=O)=O)OC(c3ccccc3)=O)O)C2=C(C)[C@H]1OC([C@@H]([C@H](c1ccccc1)NC(c1ccccc1)=O)O)=O Chemical compound CC(C)([C@@](C1)([C@H](C([C@]2([C@@H](C[C@@H]3O)OC2)OC(C)=O)[C@]3(C)C([C@@H]2OC(C)=O)=O)OC(c3ccccc3)=O)O)C2=C(C)[C@H]1OC([C@@H]([C@H](c1ccccc1)NC(c1ccccc1)=O)O)=O RCINICONZNJXQF-VAZQATRQSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4400608P | 2008-04-10 | 2008-04-10 | |
| US61/044,006 | 2008-04-10 | ||
| PCT/US2008/076179 WO2009126175A1 (en) | 2008-04-10 | 2008-09-12 | Compositions of hydrophobic taxane derivatives and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011517683A JP2011517683A (ja) | 2011-06-16 |
| JP2011517683A5 true JP2011517683A5 (enExample) | 2012-10-18 |
Family
ID=40456809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011503961A Pending JP2011517683A (ja) | 2008-04-10 | 2008-09-12 | 疎水性タキサン誘導体の組成物およびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP2011517683A (enExample) |
| KR (2) | KR20150136137A (enExample) |
| RU (1) | RU2010145529A (enExample) |
| TW (1) | TW200942233A (enExample) |
| WO (1) | WO2009126175A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| SI1931321T1 (sl) | 2005-08-31 | 2019-07-31 | Abraxis Bioscience, Llc | Sestave, ki zajemajo slabo vodotopne farmacevtske učinkovine in antimikrobna sredstva |
| RU2559570C2 (ru) | 2009-04-15 | 2015-08-10 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Композиции без приона на основе наночастиц и способы их получения |
| US9211283B2 (en) * | 2009-12-11 | 2015-12-15 | Biolitec Pharma Marketing Ltd | Nanoparticle carrier systems based on human serum albumin for photodynamic therapy |
| NZ602382A (en) | 2010-03-26 | 2014-11-28 | Abraxis Bioscience Llc | Methods of treatment of hepatocellular carcinoma |
| CN105147613A (zh) | 2010-03-29 | 2015-12-16 | 阿布拉科斯生物科学有限公司 | 增强药物递送和治疗剂有效性的方法 |
| MX364637B (es) | 2010-03-29 | 2019-05-03 | Abraxis Bioscience Llc Star | Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc. |
| CA2801645A1 (en) | 2010-06-04 | 2011-12-08 | Abraxis Bioscience, Llc | Use of nanoparticules comprising a taxane and an albumin in the treatment of pancreatic cancer |
| CN105832703A (zh) | 2010-06-07 | 2016-08-10 | 阿布拉科斯生物科学有限公司 | 治疗增殖性疾病的联合治疗方法 |
| EP2447268A1 (en) * | 2010-10-29 | 2012-05-02 | INDENA S.p.A. | Crystalline form of 13-[(N-tert-butoxycarbonyl)-2'-O-hexanoyl-3-phenylisoserinyl]-10-deacetylbaccatin III |
| SG11201401946QA (en) | 2011-11-01 | 2014-05-29 | Celgene Corp | Methods for treating cancers using oral formulations of cytidine analogs |
| WO2013085902A1 (en) | 2011-12-05 | 2013-06-13 | The University Of Texas M.D. | Combination therapy methods for treating an inflammatory breast cancer |
| AU2012352167B2 (en) | 2011-12-14 | 2017-07-27 | Abraxis Bioscience, Llc | Use of polymeric excipients for lyophilization or freezing of particles |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| JP6349381B2 (ja) | 2013-03-12 | 2018-06-27 | アブラクシス バイオサイエンス， エルエルシー | 肺がんを処置する方法 |
| JP6309610B2 (ja) | 2013-03-14 | 2018-04-11 | アブラクシス バイオサイエンス， エルエルシー | 膀胱がんを処置する方法 |
| WO2015195634A1 (en) | 2014-06-17 | 2015-12-23 | Celgne Corporation | Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| EA036790B1 (ru) | 2015-06-29 | 2020-12-22 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способ лечения злокачественной пекомы |
| BR112018005200A2 (pt) * | 2015-09-16 | 2018-10-09 | Dfb Soria Llc | liberação de nanopartículas de fármaco e métodos de uso dos mesmos |
| WO2019090272A1 (en) | 2017-11-06 | 2019-05-09 | Flx Bio, Inc. | Chemokine receptor modulators for treatment of epstein barr virus positive cancer |
| CA3094453A1 (en) | 2018-03-20 | 2019-09-26 | Abraxis Bioscience, Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
| JP2022553426A (ja) | 2019-10-28 | 2022-12-22 | アブラクシス バイオサイエンス， エルエルシー | アルブミンおよびラパマイシンの医薬組成物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6749868B1 (en) * | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| WO1994018954A1 (en) * | 1993-02-22 | 1994-09-01 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of biologics and compositions useful therefor |
| PL187738B1 (pl) * | 1995-09-12 | 2004-09-30 | Liposome Co Inc | Hydrofobowa pochodna taksanu, kompozycja farmaceutyczna oraz jej zastosowanie |
| NZ502500A (en) * | 1997-06-27 | 2002-03-28 | Vivorx Pharmaceuticals Inc | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| HK1047896A1 (zh) * | 2000-02-02 | 2003-03-14 | 佛罗里达州立大学研究基金有限公司 | C10杂取代的乙酸基紫衫烷抗肿瘤剂 |
| CN101146514B (zh) * | 2005-02-18 | 2013-03-27 | 阿布拉西斯生物科学公司 | 用于整合入医疗装置的疏水性改善的药物 |
| MX2007010394A (es) * | 2005-02-24 | 2008-02-19 | Elan Pharma Int Ltd | Formulaciones nanoparticuladas de docetaxel y analogos del mismo. |
-
2008
- 2008-09-12 KR KR1020157031393A patent/KR20150136137A/ko not_active Ceased
- 2008-09-12 JP JP2011503961A patent/JP2011517683A/ja active Pending
- 2008-09-12 TW TW097135271A patent/TW200942233A/zh unknown
- 2008-09-12 RU RU2010145529/15A patent/RU2010145529A/ru unknown
- 2008-09-12 WO PCT/US2008/076179 patent/WO2009126175A1/en not_active Ceased
- 2008-09-12 KR KR1020107025259A patent/KR20100133475A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011517683A5 (enExample) | ||
| RU2010145529A (ru) | Композиции гидрофобных производных таксана и их применение | |
| US20250120947A1 (en) | Compounds and methods to sensitize cancer cells to cisplatin | |
| TWI316942B (en) | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents | |
| AU2009308511B2 (en) | Transition metal complexes of a bis[thiohydrazide amide] compound | |
| US12318364B2 (en) | Isoflavonoid compositions and methods for the treatment of cancer | |
| JP2009530398A5 (enExample) | ||
| JP7045985B2 (ja) | Ｅｚｈ２阻害剤を用いた髄芽腫の処置方法 | |
| JP2019510787A5 (enExample) | ||
| RU2019142507A (ru) | Композиции, способы и системы для синтеза и применение визуализирующих средств | |
| JP2009536191A5 (enExample) | ||
| JP2019522055A5 (enExample) | ||
| JP2013519653A5 (enExample) | ||
| JP2015508068A5 (enExample) | ||
| JP2013518036A5 (enExample) | ||
| KR20170141757A (ko) | 테트라하이드로나프티리디닐 프로피온산 유도체 및 이의 용도 | |
| US9072660B2 (en) | Topical itraconazole formulations and uses thereof | |
| JP2017537886A5 (enExample) | ||
| EP3922251B1 (en) | Cancer immunotheraphy adjuvant | |
| JP2014515407A5 (enExample) | ||
| RU2012150501A (ru) | Противораковые стероидные лактоны, ненасыщенные в положении 7(8) | |
| JP2015500294A (ja) | 金属過剰症を治療する経口製剤 | |
| JP2017515899A5 (enExample) | ||
| WO2017004005A1 (en) | N-acylalkyl prodrugs of multi-tyrosine kinase inhibitors and methods of use | |
| CN107108761B (zh) | 硫酸软骨素衍生物和膀胱疾病处置剂 |